

Ranolazine added to glimepiride cuts HbA1c in T2DM

18 January 2016



(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published online Jan. 8 in *Diabetes, Obesity and Metabolism*.

Jeremy Pettus, M.D., from the University of California, San Diego, and colleagues examined the efficacy of ranolazine for [glycemic control](#) in [patients](#) with type 2 diabetes on metformin or glimepiride. The authors randomized 431 and 442 patients to ranolazine versus placebo added to glimepiride or metformin background therapy, respectively. To correct for the metformin-ranolazine pharmacokinetic interaction, patients receiving ranolazine added to metformin had their metformin dose halved.

The researchers found that, compared with placebo, the addition of ranolazine to glimepiride was associated with a 0.51 percent decrease from baseline in HbA1c at 12 weeks, and near doubling of the proportion of patients achieving an HbA1c of

APA citation: Ranolazine added to glimepiride cuts HbA1c in T2DM (2016, January 18) retrieved 15 June 2019 from <https://medicalxpress.com/news/2016-01-ranolazine-added-glimepiride-hba1c-t2dm.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.